Waldenstrom's Macroglobulinemia Clinical Trial
— CaRDOfficial title:
Carfilzomib, Rituximab, and Dexamethasone (CaRD) in Waldenstrom's Macroglobulinemia
NCT number | NCT01470196 |
Other study ID # | 11-279 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | October 2011 |
Est. completion date | September 2016 |
Verified date | October 2018 |
Source | Dana-Farber Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Carfilzomib is a drug that has shown anti-tumor activity by inhibiting the proteasome within
the cell, which is responsible for degrading or breaking down a wide variety of proteins.
Carfilzomib has not been approved by the FDA.
Rituximab and dexamethasone are often used to treat Waldenstrom's Macroglobulinemia (WM),
alone or in combination with other drugs. Combinations with rituximab, dexamethasone and
proteasome inhibitors, like carfilzomib, show high levels of activity in WM patients.
In this research study, the investigators are testing the safety and efficacy of Carfilzomib
when used along with Rituximab and Dexamethasone as a possible treatment for Waldenstrom's
Macroglobulinemia.
Status | Completed |
Enrollment | 31 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of Waldenstrom's Macroglobulinemia - Symptomatic disease - Measurable disease - Life expectancy of greater than 12 weeks - Adequate organ and marrow function - CD20 positive based on any previous performed bone marrow immunohistochemistry or flow cytometric analysis - Disease free of prior malignancies for >/= 5 years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast Exclusion Criteria: - More than one prior therapy - Previous therapy with a proteasome inhibitor or rituximab - Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or not recovered from adverse events due to agents administered more than 4 weeks earlier - Currently receiving treatment for any malignancy - Major surgery within 21 days prior to study entry - Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to study entry - Uncontrolled hypertension or uncontrolled diabetes - Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to study entry - Known history of allergy to Captisol - Receiving any other study agents - Known brain metastases - History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib, rituximab, and/or dexamethasone - Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment - Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Pregnant or lactating - HIV-positive on combination antiretroviral therapy |
Country | Name | City | State |
---|---|---|---|
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Dana-Farber Cancer Institute | Amgen |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Response Rate | Overall Response Rate= Minor response (>25%-50% reduction in serum IgM from baseline + Partial Response (>50-90% reduction in serum IgM from baseline) + Very Good Partial Response (>90% reduction in serum IgM from baseline) + Complete Response (resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly). | 4 years | |
Primary | Neuropathy Incidence Rate | Number and percentage of participants who experienced neuropathy attributable to CaRD therapy | 3 years | |
Primary | Time to Progression | Progression-free survival is the defined as the time from study entry to disease progression (PD) or death. Patients without PD are censored at the date of last disease evaluation. PD is defined as a greater than 25% increase in serum IgM and 500mg/dL absolute increase from the lowest attained response value as determined by serum electrophoresis, confirmed by at least one other investigation, or progression of clinically significant disease related symptom(s). | 4 years | |
Primary | Major Response Rate | Major Response Rate= Partial Response (>50-90% reduction in serum IgM from baseline) + Very Good Partial Response (>90% reduction in serum IgM from baseline) + Complete Response (resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly). | 4 years | |
Primary | Very Good Partial Response and Complete Response Rate | This is the rate of VGPR and CR in patients on CaRD therapy. Very good partial responses are >90% reduction in serum IgM from baseline. Complete response is defined as having resolution of all symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly. | 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02566265 -
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
|
Phase 2 | |
Completed |
NCT00422656 -
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT00150462 -
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
|
Phase 1 | |
Completed |
NCT00165295 -
Sildenafil Citrate in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Terminated |
NCT00142168 -
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Suspended |
NCT02439138 -
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
|
Phase 2 | |
Completed |
NCT00250926 -
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
|
Phase 2 | |
Terminated |
NCT03225716 -
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
|
Phase 1 | |
Terminated |
NCT01744912 -
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT02363439 -
Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401
|
Phase 1/Phase 2 | |
Completed |
NCT00976248 -
Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Terminated |
NCT00575965 -
Simvastatin in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT00919139 -
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.
|
N/A | |
Completed |
NCT01614821 -
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Active, not recruiting |
NCT01078974 -
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
|
Phase 1 | |
Completed |
NCT00481871 -
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00142116 -
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT02092909 -
Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
|
Phase 1/Phase 2 | |
Completed |
NCT00807677 -
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01046006 -
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
|
Phase 2 |